Collplant enriches portfolio of rhcollagen-based bioinks with launch of collink.3dtm 50l in powder form

Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3d bioprinting applications collink.3d™ 50l strengthens collplant's platform of bioink solutions to biopharma and academic customers seeking animal-free alternatives with improved bio-functionality, safety and reproducibility  rehovot, israel , jan. 3, 2023 /prnewswire/ -- collplant (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the launch of collink.3dtm 50l, a recombinant human collagen (rhcollagen)-based bioink in a powder form for use in a wide range of 3d bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs. collink.3dtm 50l, the result of a comprehensive development effort, is a tunable bioink that can be easily reconstituted to form solutions with application-specific concentrations, formulated with other components and crosslinked to form hydrogels that meet the demand for specific geometric, physical and biological properties of different 3d constructs.
CLGN Ratings Summary
CLGN Quant Ranking